Meeting
2019 ASCO Annual Meeting
An open label, multicenter, phase II study of KRT-232, an oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel cell carcinoma (MCC) who have failed treatment with anti-PD-1/L1 immunotherapy.
Authors
Glenn J. Hanna
Dana-Farber Cancer Institute, Boston, MA
Glenn J. Hanna , James A. DeCaprio , John Hai Ming Mei , Jesse S. McGreivy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03787602
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS9602)
DOI
10.1200/JCO.2019.37.15_suppl.TPS9602
Abstract #
TPS9602
Poster Bd #
169a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs.
First Author: Montaser F. Shaheen
Poster
2022 ASCO Annual Meeting
Immune-related adverse effects of long-term PD-1/PD-L1 inhibtor treatment.
First Author: Sarah Kim
Poster
2022 ASCO Annual Meeting
Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.
First Author: Meredith McKean
Poster
2021 Gastrointestinal Cancers Symposium
Response to PD-1 and PD-L1 based immunotherapy in MSS advanced colorectal cancer is impacted by metastatic disease sites.
First Author: Marwan Fakih